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This report summarises a workshop convened by the UK Food Standards Agency (FSA) on 11 September 2006 to review the results of
three FSA-funded studies and other recent research on effects of the dietary n-6:n-3 fatty acid ratio on cardiovascular health. The
objective of this workshop was to reach a clear conclusion on whether or not it was worth funding any further research in this area. On
the basis of this review of the experimental evidence and on theoretical grounds, it was concluded that the n-6:n-3 fatty acid ratio is
not a useful concept and that it distracts attention away from increasing absolute intakes of long-chain n-3 fatty acids which have
been shown to have beneficial effects on cardiovascular health. Other markers of fatty acid intake, that more closely relate to physiological
function, may be more useful.
Polyunsaturated fatty acids: Cardiovascular disease: Fish oil
The UK Food Standards Agency (FSA) convened a work-
shop on 11 September 2006 to review the results of three
FSA-funded studies and other recent research on effects of
the dietary n-6:n-3 fatty acid ratio on cardiovascular health.
The objective of this workshop was to reach a clear con-
clusion on whether or not it was worth funding any further
research in this area. Professors Bill Harris and Philip
Calder presented overviews of the literature in order to set
the scene. These two general presentations were followed
by three specific presentations, given by Dr Julie Lovegrove,
Professor Tom Sanders and Dr Carmel Moore, each of which
focused on the results from an individual FSA-funded pro-
ject. The presentations were followed by a general discussion
of the scientific issues raised. The workshop was chaired by
Professor Rudolph Riemersma.
Uses and abuses of the n-6:n-3 fatty acid ratio
Professor Bill Harris presented his theoretical concerns with
the n-6:n-3 fatty acid ratio and then discussed the experimen-
tal evidence for the usefulness of the ratio(1). Three theoretical
concerns with the n-6:n-3 fatty acid ratio were identified. First,
depending on how the proportion of n-6 fatty acids changed,
the proportion of n-3 fatty acids could decrease, remain
unchanged or increase and still lead to a lowering of the
n-6:n-3 fatty acid ratio. This would be a concern as the phys-
iological effects of a decrease, no change or an increase in the
proportion of n-3 fatty acids are likely to be very different. A
second concern with the n-6:n-3 fatty acid ratio, as frequently
used, is its failure to distinguish between the n-3 fatty acids
a-linolenic acid (ALA), EPA and DHA or the n-6 fatty
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acids linoleic acid (LA) and arachidonic acid (AA). It is well
established that the effects of the 18-carbon n-3 fatty acids on,
for example, TAG lowering are very different from those of
the 20- or 22-carbon n-3 fatty acids. A third concern is that
the ratio assumes that both higher levels of n-6 fatty acids
and lower levels of n-3 fatty acids increase cardiovascular
risk. This is not likely to be the case, as higher levels of
both n-6 and n-3 fatty acids are associated with reduced cardi-
ovascular risk (see below).
The basis of the alleged in vivo antagonism between n-6 and
n-3 fatty acids is the competition between the two classes of
fatty acid for metabolism by D6-desaturase. If this competition
occurs in vivo, then increasing dietary LA should result in
increased production of AA, which will compete with EPA
for incorporation into membrane phospholipids. As a result
more AA might be available for metabolism by either the
cyclo-oxygenase or lipoxygenase enzymes into a variety of
eicosanoids. Since eicosanoids derived from AA tend to be
more potent stimulators of platelet aggregation and inflam-
mation than eicosanoids derived from EPA, then a high diet-
ary LA intake should encourage a pro-inflammatory and
pro-aggregatory state. Although this is a clear potential bio-
chemical mechanism for opposing actions of n-6 and n-3
fatty acids, a crucial question is whether there is any exper-
imental evidence in adults consuming mixed diets for vari-
ations in the dietary n-6:n-3 fatty acid ratio having the
predicted physiological effects.
One prediction of the hypothesis is that a high n-6:n-3 fatty
acid ratio in the diet would inhibit the conversion of ALA to
EPA. This prediction has been tested recently in human sub-
jects(2). Twenty-nine healthy volunteers ate a control diet
with an n-6:n-3 fatty acid ratio of 19:1 for 4 weeks. The sub-
jects were then randomised to receive two diets for 6 weeks
with the same n-6:n-3 fatty acid ratio (7:1) designed by
either reducing LA while keeping ALA constant or by increas-
ing ALA while keeping LA constant. At the end of each
period the conversion of [U-13C]ALA to EPA and DHA was
measured. By comparison with the control diet, the rate of
conversion did not change in the low LA group in which
ALA was kept constant but increased when dietary ALA
increased without changing LA. Thus the amounts of ALA
and LA in the diet, but not the n-6:n-3 fatty acid ratio, deter-
mine ALA conversion to EPA. The hypothesis predicted that
rates of conversion of ALA should have decreased in response
to a high n-6:n-3 ratio.
A second prediction of the hypothesis is that high intakes of
n-6 fatty acids should be associated with high risk of CVD and
should antagonise effects of n-3 fatty acids. This prediction is
not supported by the results of either epidemiological studies
or randomised controlled trials. In the National Heart, Lung
and Blood Institute Family Heart Study high intakes of ALA
or LA were both associated with low risk of CVD in a
cross-sectional study(3). In the Health Professionals Follow-
up Study the LA content of the diet had no effect on the ability
of long-chain n-3 fatty acids or ALA to lower the risk of
sudden cardiac death(4). The Health Professionals Follow-up
Study also showed that intakes of LA were inversely associ-
ated with CHD risk in men(5) and the Nurses’ Health Study
showed the same association in women(6). In the Western
Electric Study intakes of PUFA were inversely associated
with risk of death from CHD(7). The results of randomised
controlled trials do not support the second prediction either.
Four trials have demonstrated that increasing the intake of
LA lowers the risk of total cardiovascular events(8–11). In
addition, a systematic review of primary and secondary pre-
vention trials where SFA were replaced by PUFA showed a
reduction in coronary events with a non-significant trend for
a reduction in all-cause mortality(12).
A third prediction of the hypothesis is that a high n-6:n-3 fatty
acid ratio in the diet should elevate markers of inflammation.
Three studies have been published on the relationship between
the level of inflammatory markers and either plasma levels or
dietary intakes of n-3 or n-6 fatty acids. In one study it was
found that higher intakes of PUFA (about 90% n-6) or n-3
fatty acids were both associated with lower levels of two soluble
receptors of TNF-a(13). A second study confirmed the inverse
relationship between intakes of EPA þ DHA and the plasma
levels of the two soluble receptors for TNF-a but a relationship
was not demonstrated for n-6 fatty acid intake(14). A third epide-
miological study looked at the relationship between plasma
levels of fatty acids and a variety of inflammatory markers(15).
Several statistically significant associations were found, but in
each case, the long-chain n-6 and the n-3 fatty acids were related
to inflammatory markers in the same way. Hence there is no evi-
dence that n-6 fatty acids elevate markers of inflammation. On
the contrary, they appear to be directly associated with anti-
inflammatory states, as are the n-3 fatty acids.
The hypothesis also predicts that if cases of CHD and con-
trols are compared then serum levels of n-6 fatty acids should
be higher and serum levels of n-3 fatty acids should be lower
in the cases than in the controls. Thirteen such studies have
recently been reviewed and it was found that serum
EPA þ DHA was significantly lower in the cases than in the
controls as predicted(16). However, contrary to the hypothesis,
serum or tissue AA levels also tended to be lower in the cases
than in the controls.
A final prediction of the hypothesis is that lowering dietary
intake of LA should decrease tissue AA levels which would
then allow EPA to more effectively compete with AA for
metabolism and the subsequent production of less potent eico-
sanoids would be greater. However, it was found that the pro-
portion of AA in plasma phospholipids tended to be lower in
response to a diet containing 12% of energy as LA than to one
containing only 6%(17). In a second study in which diets con-
taining four different levels of LA were fed it was found that
neither erythrocyte nor platelet AA was related to the LA con-
tent of the diet(18). While the tissue content of AA cannot be
lowered by lowering the LA content of the diet (except in
frank LA deficiency states) it can be readily lowered by
increasing the EPA þ DHA content of the diet. Thus
increasing the intake of very-long-chain (VLC) n-3 PUFA
(i.e. EPA þ DHA) by 1, 2 or 3 g/d lowered the erythrocyte
content of n-6 highly unsaturated fatty acids by 26, 39 and
48% respectively(19). Thus increasing the intake of n-3 fatty
acids is a more effective way of lowering tissue AA content
than decreasing the intake of n-6 fatty acids.
On the basis of this review of the experimental evidence
and on theoretical grounds, Professor Harris concluded that
the n-6:n-3 fatty acid ratio is not a useful concept and that it
distracts attention away from increasing absolute intakes of
VLC n-3 fatty acids which have been shown to have beneficial
effects on cardiovascular health(20–22).
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Meaning and usefulness of the n-6:n-3 fatty acid ratio
Professor Philip Calder discussed the meaning and usefulness
of the n-6:n-3 fatty acid ratio. He opened with the contention
that the n-6:n-3 fatty acid ratio is potentially useful because of
the competition between LA and ALA for metabolism by D6-
desaturase. As a result, the ratio may say something about the
relative rates of metabolism of the two fatty acids in vivo. In
the absence of high intakes of oily fish and fish oil supplemen-
tation the dietary n-6:n-3 fatty acid ratio approximates the
dietary LA:ALA ratio, as LA makes up about 95% of the
n-6 fatty acid intake and ALA about 90% n-3 fatty acid intake.
Four assumptions that are frequently made about the n-6:n-3
fatty acid ratio were highlighted. First, that all ways of chan-
ging the ratio are equivalent. Second, that a decrease in the
ratio will, by definition, be beneficial. Third, that changing
the ratio will have a physiological impact. Fourth, that the
ratio can be used when n-6 and n-3 PUFA other than LA and
ALA are consumed in the diet in significant amounts.
There are many ways of arriving at the same ratio either
by changing LA intake and keeping ALA intake constant, or
by keeping LA intake constant and changing ALA intake,
or by changing both LA and ALA intakes. Experiments car-
ried out by Goyens et al.(2) clearly demonstrate that using
different strategies to change the ratio can produce different
results in terms of LA and ALA metabolism and the fatty
acid composition changes observed in target pools. Thus,
not all ways of changing the ratio are equivalent in their effect.
Contrary to assumptions frequently made, a decrease in the
n-6:n-3 fatty acid ratio is not always beneficial. Although there
is ample evidence that increasing ALA intake (i.e. decreasing
the n-6:n-3 fatty acid ratio) can increase plasma, cell and
tissue EPA concentrations(23,24), increasing ALA intake does
not increase DHA status and may even decrease it(25,26).
Thus, a decrease in the n-6:n-3 fatty acid ratio may not
always be beneficial.
While increasing intake of either LA or ALA in place of
SFA will lower CVD risk, changing the n-6:n-3 fatty acid
ratio of the diet by increasing ALA intake at the expense of
LA may make very little difference to risk of CVD(22,23,27).
Thus, changing the n-6:n-3 fatty acid ratio may not have
any physiological impact.
There is an increasing tendency to include fatty acids other
than LA and ALA in the calculation of the n-6:n-3 fatty acid
ratio of foods or the diet. This assumes that all n-6 fatty acids
are equivalent and that all n-3 fatty acids are equivalent and
ignores the metabolic rationale that gave rise to the ratio in
the first place. The idea that all n-6 fatty acids are physiologi-
cally equivalent and all n-3 fatty acids, including ALA, EPA
and DHA, are physiologically equivalent is untenable. Thus,
adding 2 g ALA to the diet will decrease the n-6:n-3 ratio
but the effects on cardiovascular risk will be minimal, whereas
adding 2 g EPA þ DHA to the diet, which will also decrease
the n-6:n-3 ratio, is likely to have an impact on cardiovascular
risk. Thus, fatty acids other than LA and ALA should not be
included when calculating the n-6:n-3 fatty acid ratio and, fur-
thermore, the ratio is of limited usefulness when intake of
longer-chain n-3 fatty acids (EPA and DHA) is significant.
It was concluded that the dietary n-6:n-3 fatty acid ratio is
of limited usefulness. However, other markers of fatty acid
intake that more closely relate to physiological function may
be more useful. These alternatives could include n-6 or n-3
highly unsaturated fatty acids as a percentage of total highly
unsaturated fatty acids in plasma, cells or tissues(28) or the
n-3 index (EPA þ DHA as a prcentage of fatty acids in eryth-
rocytes)(29), both of which are related to cardiovascular risk.
Finally, the AA:EPA þ DHA ratio in cells or tissues may be
a useful functional marker(30,31) and disease indicator32).
n-6:n-3 Polyunsaturated fatty acid ratio in Asians
Dr Julie Lovegrove presented the results of an FSA-funded
project on the dietary n-6:n-3 PUFA ratio in UK Asians and
its relevance to cardiovascular risk and modification by dietary
means. It is known that the prevalence of CVD, type 2 dia-
betes and the metabolic syndrome is higher in individuals
living in the UK and originating from the Indian subcontinent
than it is in European natives(33). However, the reasons for this
excess disease risk are unclear. Genetic predisposition and
environmental factors including diet have been proposed as
possible contributing factors, with low VLC n-3 PUFA
status in the context of a high n-6 PUFA intake hypothesised
as a potential contributing factor.
The results of the project showed that UK Sikh men and
women living in and around the Reading area had a signifi-
cantly higher platelet membrane phospholipid n-6:n-3 PUFA
ratio and a significantly lower n-3 index compared with
matched Europeans(34). This was also reflected in a signifi-
cantly lower dietary intake of total VLC n-3 PUFA and a sig-
nificantly higher dietary n-6:n-3 PUFA ratio(34). Following
supplementation of the Sikh diet with 2·4 g EPA þ DHA/d
for 12 weeks, the platelet phospholipid n-6:n-3 PUFA ratio
and n-3 index normalised to levels observed in the matched
European natives(34). This was accompanied by a significant
reduction in plasma TAG and apo B-48 concentrations.
Results from this study suggest that UK Sikhs are very respon-
sive to VLC n-3 PUFA supplementation irrespective of back-
ground dietary n-6:n-3 PUFA ratio.
In another study the intake of dietary n-6 PUFA was
increased by the use of specially formulated oils and spreads,
thereby changing the background dietary n-6:n-3 PUFA ratio.
UK Sikh men were randomised to follow a diet with an
n-6:n-3 ratio of 16 or 9 for a 6-week period. It was observed
that there were small but significant effects on the platelet phos-
pholipid n-6:n-3 fatty acid ratio and the n-3 index(35). However,
this was not associated with changes in insulin sensitivity or
blood lipid profiles. When both groups were then given a sup-
plement of 2·4 g EPA þ DHA/d for a further 6 weeks, in
addition to the specialised foods, significant reductions in fast-
ing plasma TAG levels were observed in both groups, although
no differences were observed between the groups. However,
the group eating the diet with an n-6:n-3 fatty acid ratio of 16
did show a significant reduction in postprandial plasma TAG
and LDL3 levels not seen in the group eating a diet with an
n-6:n-3 ratio of 9(36). Hence, the lower background dietary
n-6:n-3 PUFA ratio did not beneficially modulate the effects
of EPA þ DHA on plasma TAG levels or other CVD risk
factors measured.
Dr Lovegrove concluded that the results of these studies
provided little support for the idea that the dietary n-6:n-3
fatty acid ratio modifies CVD risk.
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Quantification of the optimal n-6:n-3 fatty acid ratio
Professor Tom Sanders presented the results of an FSA-funded
project on the quantification of the optimal n-6:n-3 fatty acid
ratio in the UK diet. This research group carried out a random-
ised controlled trial in older men and postmenopausal women
who had a mean 10-year risk of CHD of 18%(37,38). In a ran-
domised, parallel design in 258 subjects aged 45–70 years,
they compared four diets providing 6% of energy as PUFA
with an n-6:n-3 ratio between 5:1 and 3:1 with a control
diet that had an n-6:n-3 ratio of 10:1. The diets were enriched
in ALA, EPA, DHA or EPA þ DHA.
The diets enriched in EPA þ DHA significantly increased
the proportion of EPA and DHA found in both plasma and
erythrocyte lipids. The findings were in line with the predic-
tions of Lands et al.(39). The diets with an n-6:n-3 fatty acid
ratio of about 3:1 containing EPA þ DHA significantly low-
ered both fasting and 3 h postprandial TAG concentrations
and the proportion of small dense LDL decreased while the
proportion of HDL2 increased. In women not using hormone
replacement therapy, diets enriched in EPA þ DHA signifi-
cantly increased total and LDL-cholesterol levels. However,
fasting plasminogen activator inhibitor 1, tissue plasminogen
activator, fibrinogen, factors XIIa, VIIc, VIIa and VIIag and
postprandial factor VIIa were unaffected by diet. Similarly
there were no effects of diet on insulin sensitivity, postpran-
dial NEFA response or postprandial lipoprotein lipase activi-
ties. By contrast, arterial stiffness was significantly lower in
response to the diets enriched in EPA þ DHA although
there were no significant effects on blood pressure or endo-
thelial function. Lowering the n-6:n-3 fatty acid ratio by
increasing the intake of EPA þ DHA increased levels of trans-
forming growth factor b1 and decreased levels of C-reactive
protein in comparison with diets enriched in ALA. There
were no other significant effects of diet on markers of inflam-
mation or haemostasis.
Professor Sanders concluded that the results of this project
do not support the idea that consumption of ALA is equival-
ent to consumption of EPA þ DHA with respect to the
effects of these fatty acids on CVD risk markers. He also
concluded that decreasing the n-6:n-3 ratio to approximately
3:1 by increasing the intake of EPA and DHA lowers fasting
and postprandial plasma TAG concentrations in older indi-
viduals but does not influence haemostatic factors. The
results from this study, however, did indicate that the
intake of LA was a determinant of the proportion of EPA
and DHA in membrane lipids: the higher the intake of LA
the lower the proportion of EPA and DHA. This was in
agreement with observational data from a comparison of
vegans, vegetarians and omnivores in the Oxford cohort of
the EPIC study(40). Overall, the findings indicate that in the
context of a total PUFA intake of 6% of energy, decreasing
the ratio by increasing the intake of VLC n-3 fatty acids to
approximately 1–1·5 g/d resulted in potentially beneficial
effects with regard to cardiovascular risk.
Impact of changes in the dietary n-6:n-3 polyunsaturated
fatty acid ratio on risk factors for disease
Dr Carmel Moore presented the results of an FSA-funded
project to examine the public health impact of changes in
the dietary n-6:n-3 PUFA ratio. This research group carried
out a randomised controlled trial with a parallel-group
design(41). At baseline there were 142 overweight subjects ran-
domly assigned to eat either a control diet or diets containing
two portions of white fish (providing 0·7 g EPA þ DHA/week)
or two portions of oily fish (providing 4·5 g EPA þ DHA/
week) each against a background of use of either rapeseed
oil (low LA:ALA) or sunflower-seed oil (high LA:ALA) for
24 weeks. Dietary n-6:n-3 fatty acid ratios varied between
6·9:1 and 8·0:1 at baseline and during the intervention were
7:1 (control), 6:1 (white fish–rapeseed), 11:1 (white fish–sun-
flower-seed), 4:1 (oily fish–rapeseed) and 6:1 (oily fish–sun-
flower-seed).
Plasma levels of EPA and DHA were significantly lower in
response to the white fish diets than in response to either of the
oily fish diets. In addition, plasma TAG levels were signifi-
cantly lower in the oily fish groups than in the white fish–sun-
flower-seed oil group(41). Other markers of cardiovascular risk
including insulin sensitivity, other plasma lipids including
total, LDL- and HDL-cholesterol, a variety of markers of hae-
mostatic and inflammatory status did not differ amongst the
five dietary groups.
Dr Moore concluded that two portions of oily fish per week
can lead to significant reductions in fasting plasma TAG levels
in comparison with two portions of white fish per week. There
were no effects of the n-6:n-3 fatty acid ratio of the
diet although it should be emphasised that this study looked
at a comparatively narrow range of n-6:n-3 ratios.
Recommendations
The following recommendations were made:
(1) Based upon theoretical and scientific grounds (described
earlier), use of the n-6:n-3 fatty acid ratio to estimate
CVD risk should be abandoned.
(2) Given the lack of effects of varying the dietary n-6:n-3
fatty acid ratio on CVD risk factors, further research in
this area is unlikely to be fruitful.
(3) Future research on dietary fatty acids would benefit from
focusing on the effects of absolute amounts of individual
n-6 and VLC n-3 fatty acids on cardiovascular risk fac-
tors and other physiological outcomes related to risk of
chronic disease.
(4) It would be desirable wherever possible to investigate the
effects of dietary fatty acids on CVD endpoints rather
than on risk factors.
(5) Further studies are needed to identify effects of dietary
fatty acids on insulin sensitivity as this underlies the
abnormalities of the metabolic syndrome.
Attendees
Professor Rudolph Riemersma, University of Edinburgh; Pro-
fessor William Harris, University of South Dakota; Professor
Philip Calder, University of Southampton; Dr Julie Lovegrove
and Dr Parveen Yaqoob, University of Reading; Professor
Tom Sanders and Dr Fiona Lewis, King’s College, London;
Dr Carmel Moore and Dr Susan Jebb, MRC Human Nutrition
Research, Cambridge; Dr Judy Buttriss, British Nutrition
Foundation, London; Dr Jason Gill, University of Glasgow;
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Dr Bruce Griffin, University of Surrey; Dr Frank Thies, Uni-
versity of Aberdeen; Dr John Stanley, Trinity College and St
Hugh’s College, Oxford; Dr Alison Tedstone, Dr Elaine
Stone, Ms Rachel Elsom and Ms Lynda Harrop, Food Stan-
dards Agency, London, UK.
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